Array Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

ARRY 6.78 -0.02 (-0.29%)
price chart
Array Biopharma Inc (NASDAQ:ARRY), Peregrine Pharmaceuticals (NASDAQ ...
Array Biopharma Inc (NASDAQ:ARRY) fell -1.31% to close last trading session at $6.80. The company, on June 06, 2015, announced that its Chief Executive Officer, Ron Squarer, will present at the Cantor Fitzgerald 2015 Healthcare Conference in New York ...
Active Stocks Alert: Visa Inc (NYSE:V), Array Biopharma Inc (NASDAQ:ARRY)
Visa Inc, introduced additions to the FIDO 1.0 specifications with new transport protocols for FIDO U2F - Bluetooth Classic and Low Energy (BLE), and Near Field Communication (NFC).
Zacks Rating on Array BioPharma Inc.
Array BioPharma Inc. (NASDAQ:ARRY) remains a strong buy in the latest set of rankings. The shares has received an average rating of 1 by 7 analysts.
WallStreet Morning Information: Array BioPharma Inc. (ARRY), Lakeland ...  WallStreet Scope
Why Shares in Array BioPharma, Inc. Are Soaring Higher
What: Shares in Array BioPharma (NASDAQ:ARRY) are rallying by more than 10% after the company released its first quarter financial results and offered up insight into its pipeline.
Trade-Ideas: Array BioPharma (ARRY) Is Today's "Dead Cat Bounce ...
Array BioPharma's (ARRY) CEO Ron Squarer on Q3 2015 Results -- Earnings ...  Seeking Alpha
Why Array Biopharma Inc's Shares Skyrocketed
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Array Biopharma Gets Rights to Second Novartis Cancer Drug  Xconomy
Analyst Price Target Update on Array BioPharma Inc.
Array BioPharma Inc. (NASDAQ:ARRY): According to 6 Analysts, The short term target price has been estimated at $ 11.The target price could deviate by a maximum of $2.45 from the forecast price.
Array BioPharma Inc. (ARRY) is Trading Lower on Unusual Volume for July 01
Stock's Trend Analysis Report: Array Biopharma Inc (NASDAQ:ARRY ...  Investor Wired
Insider Selling: Array Biopharma Inc (NASDAQ:ARRY)'s director Charles Baum ...
Charles Baum, the well informed person, who's the present director of Array Biopharma Inc (NASDAQ:ARRY) 7.61 -0.02 -0.26% sold roughly 25,000 shares of the firm worth roughly $184,483 U.S.
Time To Ring The Register On These Hot Biotech Plays - Array Biopharma ...  Wall Street Observer
Biotech Stocks you should dump - Array Biopharma Inc (NASDAQ:ARRY ...
... Inc. (NASDAQ:BCRX) declined -2.48% to end last trading session at $14.56. The company, on June 17, 2015, released that it has licensed RAPIVAB (peramivir injection) for the treatment of influenza to CSL Limited, a global biopharmaceutical company.
Array Biopharma Inc (NASDAQ:ARRY) a Buy: Piper Jaffray
In a research note issued to investors, Edward Tenthoff at Piper Jaffray Reiterated their Buy rating on Array Biopharma Inc (NASDAQARRY). The analyst placed a $15.00 price target on the stock which indicates a 92.31% upside to the last closing price.
Array BioPharma Inc. (NASDAQ:ARRY) Price Target Update
Array BioPharma Inc. (NASDAQ:ARRY) shares are expected to touch $11 in the short term. This short term price target has been shared by 6 analysts.